Galera Shareholders Approve Governance Changes and Share Increase

An update from Galera Therapeutics ( (GRTX) ) is now available.

At its combined 2025 and 2026 Annual Meeting of Stockholders held on May 8, 2026, Galera Therapeutics’ shareholders elected one Class III director to serve until the 2028 annual meeting and two Class I directors to serve until the 2029 annual meeting, while also ratifying KPMG LLP as the independent auditor for the fiscal year ending December 31, 2026. Shareholders approved the company’s executive compensation in a Say-on-Pay vote, endorsed holding Say-on-Pay votes annually, authorized an increase in common stock from 200 million to 400 million shares, granted stockholders the right to act by written consent, and approved a charter amendment enabling the board to implement a reverse stock split at a ratio between 1:75 and 1:200 if it chooses to do so.

These actions collectively strengthen Galera’s corporate governance flexibility, expand its capacity to issue equity, and provide tools—such as the potential reverse stock split—that can be used to manage its capital structure and stock market listing requirements. For investors and other stakeholders, the approvals signal broad shareholder support for the current leadership, compensation policies, and a more flexible framework for future corporate and financing initiatives.

Spark’s Take on GRTX Stock

According to Spark, TipRanks’ AI Analyst, GRTX is a Neutral.

The score is held down primarily by weak financial performance (no revenue, ongoing operating losses, and historically negative cash flows), despite a notable 2025 deleveraging and equity repair. Technical signals are neutral-to-modestly improving, while corporate events (merger plus $350M financing) provide a meaningful positive offset. Valuation metrics are difficult to rely on due to likely distorted earnings and no dividend data.

To see Spark’s full report on GRTX stock, click here.

More about Galera Therapeutics

Galera Therapeutics, Inc. is a biotechnology company focused on developing therapeutics, with operations governed by a board of directors and oversight from an independent registered public accounting firm. The company’s corporate governance framework includes classified board seats, annual advisory votes on executive compensation, and a capital structure allowing for adjustments to its authorized share count and stock terms.

Average Trading Volume: 338,803

Technical Sentiment Signal: Buy

Current Market Cap: $16.05M

For an in-depth examination of GRTX stock, go to TipRanks’ Overview page.